OncoMatch/Clinical Trials/NCT06944444
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
Is NCT06944444 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SSS59 for malignant tumors.
Treatment: SSS59 — This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Must have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify